Natural Killer Cell-Mediated Antibody-Dependent Cellular Cytotoxicity Against SARS-CoV-2 After Natural Infection Is More Potent Than After Vaccination.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
16 05 2022
Historique:
received: 12 11 2021
accepted: 15 02 2022
pubmed: 25 3 2022
medline: 20 5 2022
entrez: 24 3 2022
Statut: ppublish

Résumé

We compared the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike-specific antibodies to induce natural killer cell-mediated antibody-dependent cellular cytotoxicity (ADCC) in patients with natural infection and vaccinated persons. Analyzing plasma samples from 39 coronavirus disease 2019 (COVID-19) patients and 11 vaccinated individuals, significant induction of ADCC could be observed over a period of more than 3 months in both vaccinated and recovered individuals. Although plasma antibody concentrations were lower in recovered patients, we found antibodies elicited by natural infection induced a significantly stronger ADCC response compared to those induced by vaccination, which may affect protection conferred by vaccination.

Identifiants

pubmed: 35323975
pii: 6552258
doi: 10.1093/infdis/jiac060
pmc: PMC8992321
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1688-1693

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Auteurs

Gereon J Rieke (GJ)

Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.

Kathrin van Bremen (K)

Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.

Jenny Bischoff (J)

Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.

Michael ToVinh (M)

Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.

Malte B Monin (MB)

Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.

Stefan Schlabe (S)

Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.
German Centre for Infection Research, Partner-site Cologne-Bonn, Bonn, Germany.

Jan Raabe (J)

Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.

Kim M Kaiser (KM)

Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.

Claudia Finnemann (C)

Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.

Alexandru Odainic (A)

Institute of Innate Immunity, Medical Faculty, University of Bonn, Bonn, Germany.
Department of Microbiology and Immunology, Doherty Institute for Infection and Immunity, University of Melbourne, Victoria, Australia.

Anushka Kudaliyanage (A)

Institute of Innate Immunity, Medical Faculty, University of Bonn, Bonn, Germany.

Eicke Latz (E)

Institute of Innate Immunity, Medical Faculty, University of Bonn, Bonn, Germany.

Christian P Strassburg (CP)

Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.

Christoph Boesecke (C)

Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.
German Centre for Infection Research, Partner-site Cologne-Bonn, Bonn, Germany.

Susanne V Schmidt (SV)

Institute of Innate Immunity, Medical Faculty, University of Bonn, Bonn, Germany.

Benjamin Krämer (B)

Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.

Jürgen K Rockstroh (JK)

Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.
German Centre for Infection Research, Partner-site Cologne-Bonn, Bonn, Germany.

Jacob Nattermann (J)

Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.
German Centre for Infection Research, Partner-site Cologne-Bonn, Bonn, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH